The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor

Cancer Immunology, Immunotherapy

Volumn 55, Issue 9, 2006, Pages 1111-1121

  Qing, Ye ^a,b   Shuo, Wang ^b   Zhihua, Wang ^c   Huifen, Zhu ^a   Ping, Lei ^a   Lijiang, Liu ^b   Xiaorong, Zhao ^a   Liming, Chao ^a   Daiwen, Xiao ^a   Yu, Huang ^a   Wei, Xing ^a   Min, Fang ^a   Zuohua, Feng ^a   Guanxin, Shen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b JIANGHAN UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Antitumor; Human mouse chimeric antibody; In vivo tumor specificity distribution; Transferrin receptor

Indexed keywords

CHIMERIC ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; IODINE 125; MONOCLONAL ANTIBODY D2C; TRANSFERRIN RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN RECOGNITION; ANTIGENICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL CYCLE G1 PHASE; CELL DEATH; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; CELL STRAIN CEM; CELL STRAIN K 562; CELL STRAIN SMMC 7721; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; EFFECTOR CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MITOCHONDRION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TARGET CELL; TUMOR CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES, ANTIBODY; BINDING, COMPETITIVE; CASPASE 8; CASPASES; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROMES C; DRUG SCREENING ASSAYS, ANTITUMOR; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; RECEPTORS, TRANSFERRIN; RECOMBINANT FUSION PROTEINS;

EID: 33744464256     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0105-7     Document Type: Article

References (29)

1. Cheng Y, Zak O, Aisen P, Harrison SC, Walz T (2004) Structure of the human transferrin receptor-transferrin complex. Cell 116(4):565-576
2. Larrick JW, Cresswell P (1979) Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J Supramol Struct 11(4):579-586
3. Sutherland R, Delia D, Schneider C, Newman R, Kemshead J et al (1981) Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc Natl Acad Sci USA 78(7):4515-4519
4. Trowbridge IS, Omary MB (1981) Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc Natl Acad Sci USA 78(5):3039-3043
5. Lloyd JM, O'Dowd T, Driver M, Tee DE (1984) Demonstration of an epitope of the transferrin receptor in human cervical epithelium - a potentially useful cell marker. J Clin Pathol 37(2):131-135
6. Raaf HN, Jacobsen DW, Savon S, Green R (1993) Serum transferrin receptor level is not altered in invasive adenocarcinoma of the breast. Am J Clin Pathol 99(3):232-237
7. Recht LD, Griffin TW, Raso V, Salimi AR (1990) Potent cytotoxicity of an antihuman transferrin receptor-ricin A-chain immunotoxin on human glioma cells in vitro. Cancer Res 50(20):6696-6700
8. Prost AC, Menegaux F, Langlois P, Vidai JM, Koulibaly M et al (1998) Differential transferrin receptor density in human colorectal cancer: a potential probe for diagnosis and therapy. Int J Oncol 13(4):871-875
9. Beguin Y, Lampertz S, De Groote D, Igot D, Malaise M et al (1993) Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia. Leukemia 7(12):2019-2025
10. Shindelman JE, Ortmeyer AE, Sussman HH (1981) Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer 27(3):329-334
11. White S, Taetle R, Seligman PA, Rutherford M, Trowbridge IS (1990) Combinations of anti-transferrin receptor monoclonal antibodies inhibit human tumor cell growth in vitro and in vivo: evidence for synergistic antiproliferative effects. Cancer Res 50(19):6295-6301
12. Kreitman RJ, Pastan I (1997) Recombinant toxins containing human granulocyte-macrophage colony-stimulating factor and either pseudomonas exotoxin or diphtheria toxin kill gastrointestinal cancer and leukemia cells. Blood 90(1):252-259
13. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC Jr (1985) Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 45(2):879-885
14. Grillo-Lopez AJ, White CA, Varns C, Shen D, Wei A et al (1999) Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 26(5 Suppl 14):66
15. Goldenberg MM (1999) A recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 21(2):309-318
16. Rastetter W, Molina A, White CA (2004) Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 55:477-503
17. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83(2):435-445
18. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V et al (2003) Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo. J Immunol 171:1581-1587
19. Wang S, Jiang L, Ye Q, Zhu H, Yang J et al (2003) Construction and expression of an anti-CD71 mouse/human chimeric antibody (D2C). Chin J Immunol 19(10):665-668
20. Adams GP, McCartney JE, Tai MS, Oppermann H, Huston JS et al (1993) Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res 53(17):4026-4034
21. Verhoff FH, Lisi PJ, Fischer CD, Teipel JW, Goldstein G et al (1980) Graphical determination of specific activity, binding constants, and antibody-site concentrations for radioimmunoassays, with application to thymopoietin. Clin Chem 26(6):718-723
22. Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA et al (1997) Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 89(14):1027-1036
23. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA (1998) Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small cell lung cancer cell lines. Br J Cancer 78(8):1035-1042
24. Tang YM, Chen MH, Chen GH, Cai CJ, He XS et al (2005) Kinetics of phytohemaglutinin-induced IFN-gamma and TNF-alpha expression in peripheral blood mononuclear cells from patients with chronic hepatitis B after liver transplantation. World J Gastroenterol 11(29):4574-4578
25. Panduri V, Weitzman SA, Chandel N, Kamp DW (2003) The mitochondria-regulated death pathway mediates asbestos-induced alveolar epithelial cell apoptosis. J Am J Respir Cell Mol Biol 28(2):241-248
26. Kovar J, Stunz LL, Stewart BC, Kriegerbeckova K, Ashman RF et al (1997) Direct evidence that iron deprivation induces apoptosis in murine lymphoma 38C13. J Pathobiol 65(2):61-68
27. Simonart T, Degraef C, Andrei G, Mosselmans R, Hermans P et al (2000) Iron chelators inhibit the growth and induce the apoptosis of Kaposi's sarcoma cells and of their putative endothelial precursors. J Invest Dermatol 115(5):893-900
28. Maclean K, Yang H, Cleveland JL (2001) Serum suppresses myeloid progenitor apoptosis by regulating iron homeostasis. Cell Biochem 82(1):171-186
29. Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M et al (2004) Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. J Blood 104(6):1793-1800